drugset / Trial / NCT04603833
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this trial is to evaluate SHR3680 combined with Docetaxel to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's Time to prostate specific antigen (PSA) progression is superior to SHR3680 or Docetaxel single drug.
Timeline
- Start
- 2020-12-02
- Primary completion
- 2022-10-01
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Rezvilutamide | Small molecule | — | — |